COMPASS Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

COMPASS Pathways (NASDAQ:CMPS) released its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.03), Zacks reports. During the same period in the prior year, the business earned ($0.62) EPS.

COMPASS Pathways Stock Up 2.3 %

NASDAQ CMPS traded up $0.16 during trading hours on Friday, reaching $7.04. 598,895 shares of the company traded hands, compared to its average volume of 423,448. The stock has a market capitalization of $481.40 million, a PE ratio of -2.97 and a beta of 2.27. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.12. COMPASS Pathways has a 12 month low of $5.01 and a 12 month high of $12.75. The company has a 50 day moving average of $6.89 and a two-hundred day moving average of $8.58.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CMPS shares. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research report on Wednesday. Canaccord Genuity Group dropped their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank of Canada started coverage on shares of COMPASS Pathways in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $43.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.